Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed drug eruption to sulindac.

D R Bruce, R B Odom

    Cutis
    |November 1, 1986
    PubMed
    Summary

    Fixed drug eruption can occur with sulindac (Clinoril). This case highlights unusual hypopigmentation during lesion healing, emphasizing physician awareness of this adverse drug reaction.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Safety of itraconazole pulse therapy for onychomycosis. An update.

    Postgraduate medicine·1999
    Same author

    Topical metronidazole maintains remissions of rosacea.

    Archives of dermatology·1998
    Same author

    Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.

    Journal of the American Academy of Dermatology·1998
    Same author

    Mycosis fungoides with onset before 20 years of age.

    Journal of the American Academy of Dermatology·1997
    Same author

    Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis.

    Cutis·1997

    Area of Science:

    • Dermatology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Fixed drug eruption (FDE) is a specific type of adverse drug reaction.
    • Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) with common clinical use.

    Observation:

    • A patient presented with a fixed drug eruption attributed to sulindac.
    • The patient exhibited an unusual manifestation of hypopigmentation as the FDE lesion healed.

    Findings:

    • The case demonstrates sulindac as a potential cause of fixed drug eruption.
    • Hypopigmentation was observed during the resolution phase of the sulindac-induced FDE.

    Implications:

    • Physicians should consider sulindac when diagnosing fixed drug eruption.
    • Awareness of FDE and its potential sequelae, like hypopigmentation, is crucial for patient management.